<code id='22608B74AD'></code><style id='22608B74AD'></style>
    • <acronym id='22608B74AD'></acronym>
      <center id='22608B74AD'><center id='22608B74AD'><tfoot id='22608B74AD'></tfoot></center><abbr id='22608B74AD'><dir id='22608B74AD'><tfoot id='22608B74AD'></tfoot><noframes id='22608B74AD'>

    • <optgroup id='22608B74AD'><strike id='22608B74AD'><sup id='22608B74AD'></sup></strike><code id='22608B74AD'></code></optgroup>
        1. <b id='22608B74AD'><label id='22608B74AD'><select id='22608B74AD'><dt id='22608B74AD'><span id='22608B74AD'></span></dt></select></label></b><u id='22608B74AD'></u>
          <i id='22608B74AD'><strike id='22608B74AD'><tt id='22608B74AD'><pre id='22608B74AD'></pre></tt></strike></i>

          fashion

          fashion

          author:focus    Page View:9

          What makes a blockbuster? Can biotech learn from Aduhelm? And how do you replace a singular regulator?

          We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We explain the debate over Vertex Pharmaceuticals’ novel pain drug, whose success in clinical trials comes with a sizable caveat. We also talk about the latest news in the life sciences, including an epitaph for Aduhelm and the retirement of an FDA icon.

          advertisement

          For more on what we cover, here’s the news on Vertex; here’s more on Aduhelm; here’s the exit interview with Janet Woodcock; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

          advertisement

          Wikipedia

          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more
          Reanimated hearts work just as well for transplants, study finds
          Reanimated hearts work just as well for transplants, study finds

          AhearttransplantoperationattheClevelandClinic.AndreaYanak/APAnewmethodofhearttransplantationthatuses

          read more
          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more

          Hospitals struggle to profit from CAR

          MedicaregenerallypaysfarmoreforCAR-Tdrugsthatareadministeredinoutpatientdepartmentsthanitdoesforinpa